{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Due to unexpectedly slow recruitment, the Sponsor decided to terminate the study after 16 patients had been enrolled. The small study population limits the evaluation of both efficacy and safety of selinexor in patients with PTCL or CTCL."},"pointOfContact":{"email":"jshah@karyopharm.com","organization":"Karyopharm Therapeutics Inc.","phone":"(617) 658-0600","title":"Jatin Shah, MD"}}